- Home
- Advocacy
- Latest News and Practice Data
- Gene patent bill threatens ability for second opinions
The CAP has warned lawmakers about the potential negative effects of the Patent Eligibility Restoration Act (PERA) on health care innovation and patient care.
In a statement for the record, we continue to oppose the controversial bill, arguing that allowing patents on genes and natural phenomena could lead to increased costs for patients and hinder medical advancements.
- Such patents could result in exclusive licensing agreements, driving up prices and limiting access to essential genetic tests.
- We note that PERA could block patients from seeking second opinions on genetic tests, as patents would prevent independent labs from offering confirmatory testing.
- By potentially allowing patents on foundational scientific tools, PERA could restrict the exchange of critical genetic information, hindering research and the development of new treatments.
Go deeper: Read our full comments. CAP members can also urge Congress to oppose PERA in our Action Center.